Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to transforming the management of disease through innovative genetic diagnostics. The company specializes in oncology, women's health, and organ health, developing cutting-edge tests that detect disease at its earliest stages. Natera's proprietary technology platform combines novel molecular biology techniques with advanced bioinformatics software and AI, enabling detection down to a single molecule in a tube of blood.
The company's mission is to make personalized genetic testing and diagnostics part of the standard of care, protecting health through earlier and more targeted interventions. Natera has developed market-leading tests including Panorama™ for prenatal screening, Signatera™ for personalized cancer detection, and Prospera™ for transplant monitoring. These innovations are backed by more than 300 peer-reviewed publications demonstrating high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories that are CLIA-certified in Austin, Texas and San Carlos, California, serving patients and healthcare providers worldwide.